Top 10 Books about Stock Investing to read in 2018. Read more.

EYES - Second Sight Medical Products

Industry: Medical Appliances & Equipment Sector: Healthcare Exchange: NASDAQ

EYES - Second Sight Medical Products

Industry: Medical Appliances & Equipment Sector: Healthcare Exchange: NASDAQ
#6458()/6724

Fri 16'th Feb 2018

PERIOD 2017-11-17 - 2018-02-16
CHANGE -2.56%
PRICE $1.71
VOLUME
Buy
TREND
Buy

MV LONG
Sell

MV SHORT
Sell

PIVOT
Sell

MACD
Sell

0.00%

Second Sight Medical Products Stock Analysis

Technical stock analysis for Fri 16'th Feb 2018

Shorts 7.21% ( 2018-01-31 )
Cash 66.2 mill
Loans n/a
Beta 3.33
ROA -135.35
Sell candidate since 2018-02-14 Gain 1.79%

Second Sight Medical Products fell by -2.56% in the last day from $1.76 to $1.71 The price has fallen in 7 of the last 10 days and is down by -16.59% for this period. Volume has increased in the last day by 267 270 shares, but on falling prices. This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 599 053 shares bought and sold for approximately $1.02 million.

Access today's Top 5 Strong Sell Candidates

Trend

Second Sight Medical Products lies in the lower part of a very wide and strong rising trend in the short term, and this will normally pose a very good buying opportunity. A break down the bottom trend line at $1.67 will firstly indicate a slower raising rate, but may also be a early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 23.54% during the next 3 months and, with 90% probability hold a price between $2.06 and $3.38 at the end of this period.

Click here for today's Top 5 Trending Companies

Signals

There are few to none technical positive signals at the moment. Second Sight Medical Products holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $1.72 and $1.91. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Thursday February 15, 2018, which indicates further falls until a new bottom pivot has been found. Second Sight Medical Products gained volume on the last day, but on falling prices. In technical terms this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-off's".

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 42 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

Second Sight Medical Products finds support from accumulated volume at $1.67. On the upside the stock meets some resistance from accumulated volume at $1.91, $2.00 and $2.01.

Support: $1.67 Price: $1.71 Resistance: $1.91

Risk

This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.13 between high and low, or 7.59%. For the last week, the stock has had a daily average volatility of 6.94%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

Overall risk:

Very Low Low Medium High Very High

Evaluation

The Second Sight Medical Products stock holds several negative signals and despite the positive trend we believe Second Sight Medical Products will perform weak in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Sell Candidate to a Strong Sell Candidate.

Trade EYES CFDs with Plus500

Your capital is at risk.

Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).

START FREE 5-DAY TRIAL